- Open $711.73
- Day Range 707.25 - 754.67
- 52 Week Range 538.01 - 754.67
- Market Cap $77.27B
- Shares Outstanding 107.19M
- Public Float 102.55M
- Beta 0.67
- Rev. per Employee $1.372M
- P/E Ratio 14.46
- EPS $50.10
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 2.93M 08/15/22
- % of Float Shorted 2.86%
- Average Volume 673.53K
Biotech and Pharma Regeneron Gets Praised by Wall Street. High-Dose Eylea Data Look ‘Strong.’
Regeneron stock price target raised to $790 from $718 at Truist
Biotech and Pharma Regeneron Stock Surges on Promising Eye Disease Drug Trial Results
Regeneron stock price target raised to $760 from $635 at Evercore ISI
Regeneron Pharmaceuticals Inc. said Thursday that an 8-milligram dose of aflibercept successfully treated patients with diabetic macular edema and wet age-related macular degeneration in a pair of pivotal trials. Regenero...
Regeneron stock to resume trading at 9:50 a.m. ET
Regeneron aflibercept 8 diabetic macular edema treatment meets primary endpoints in 2 trials
Regeneron's stock was little changed premarket prior to trading halt
Regeneron stock halted for news pending
Regeneron Pharmaceuticals Inc. topped expectations with its second-quarter financial results Wednesday morning, though revenue and profits both fell from a year earlier. The company logged net income of $852 million, or $...
Regeneron Q2 revenue $2.86 bln vs. $5.14 bln a year ago; FactSet consensus $2.79 bln
Regeneron Q2 adj. EPS $9.77; FactSet consensus $8.62
Regeneron Q2 EPS $7.47 vs. $27.97 a year ago
Companies in The News Are: REGN, JPM, CASY, GME
Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.
SVB Securities analyst David Risinger maintained a Hold rating on Regeneron (REGN - Research Report) today and set a price target of $756.00. The company's shares closed yesterday at $708.85.Risinger covers the Healthcare ...
Today's Daily Stock Market Preview – Friday September 9th 2022 Watch the TipRanks premarket news and stay up to date on stock market news before the market opens. We touch on earnings reports, the biggest gainers & los...
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.
Regeneron shares (NASDAQ:REGN) surged today after its Aflibercept met primary endpoints in two global trials for diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). Importantly, a major part of th...
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
|Name||Chg %||Market Cap|
|Gilead Sciences Inc.||
|BioNTech SE ADR||
|Samsung Biologics Co. Ltd.||
|Novozymes A/S Series B||